BGM
BGM Group Ltd. Class A Ordinary SharesBGM
BGM
About: BGM Group Ltd formerly, Qilian International Holding Group Ltd is a biopharmaceuticals, bio-extraction, and medical health business. Its product range includes oxytetracycline APIs, licorice preparations, and crude heparin sodium.
Employees: 298
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0.01% more ownership
Funds ownership: 0% [Q2] → 0.01% (+0.01%) [Q3]
0% more funds holding
Funds holding: 2 [Q2] → 2 (+0) [Q3]
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
82% less capital invested
Capital invested by funds: $20.1K [Q2] → $3.59K (-$16.5K) [Q3]
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Research analyst outlook
We haven’t received any recent analyst ratings for BGM.
Financial journalist opinion
Neutral
PRNewsWire
1 week ago
BGM Group and Jointown Deepen Cooperation, Ushering in a New Era of Pharmaceutical Development
CHENGDU, China , Dec. 19, 2024 /PRNewswire/ -- BGM Group Ltd. (NASDAQ: BGM) ("the Company" or "BGM"), Mr.
Neutral
PRNewsWire
3 weeks ago
AIX Inc. (NASDAQ:AIFU): Reshaping AI Insurance and the Healthcare Industry--A Promising Future Ahead?
HONG KONG , Nov. 29, 2024 /PRNewswire/ -- AIX Inc. (NASDAQ:AIFU) is a leading company focused on insurance agency and claims services. Recently, the company has been gradually pushing for an intelligent and diversified transformation, aiming to capture growth opportunities in the AI insurance and healthcare sectors.
Charts implemented using Lightweight Charts™